# US 2023/0398190 A1 · Compositions and methods for treating solid cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0398190 A1
- Document ID: US20230398190A1
- Status: Published application
- Kind: A1
- Application number: 18/035,480
- Filed: 2021-10-01
- Published: 2023-12-14
- Earliest claimed: 2020-11-11
- Assignees: ExOxEmis, Inc.
- Applicants: Exoxemis, Inc.
- Inventors: Robert C. Allen; Jackson T. Stephens, Jr.
- Web page: https://patentgrep.com/patent/US20230398190A1

## CPC

- A61K 38/443: {acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)}
- A61K 31/327: Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 33/20: Elemental chlorine; Inorganic compounds releasing chlorine
- A61K 33/40: Peroxides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- C12Y 111/0101: Chloride peroxidase (1.11.1.10)
- C12Y 111/02002: Myeloperoxidase (1.11.2.2)
- C12Y 111/01007: Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

Compositions and methods for treating solid cancer are provided. Specifically, the disclosure provides compositions comprising haloperoxidases, and methods comprising administering such compositions, for treating solid cancer.

## Claims

### Claim 1

A method of treating a solid cancer comprising administering an effective amount of a pharmaceutical composition comprising a haloperoxidase.

### Claim 2 (depends on 1)

The method of claim 1, wherein the haloperoxidase is selected from a group consisting of: myeloperoxidase (MPO), eosinophil peroxidase (EPO), lactoperoxidase (LPO), chloroperoxidase (CPO), functional derivatives thereof, and combinations thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein the haloperoxidase is EPO.

### Claim 4 (depends on 1)

The method of claim 1, wherein the haloperoxidase catalyzes halide oxidation and disproportionation of peroxide yielding singlet molecular oxygen resulting in one or more of:
inhibition of cancer cell growth,
inhibition of cancel cell metastases, and/or
cancer cell death.

### Claim 5 (depends on 4)

The method of claim 4, further comprising administering an effective amount of peroxide or a peroxide-producing oxidase.

### Claim 6 (depends on 5)

The method of claim 5, further comprising administering a substrate for the oxidase.

### Claim 7 (depends on 6)

The method of claim 6, wherein the peroxide-producing oxidase is glucose oxidase and the substrate is glucose.

### Claim 8 (depends on 1)

The method of claim 1, wherein the haloperoxidase is administered with a halide.

### Claim 9 (depends on 8)

The method of claim 8, wherein the halide is chloride or bromide.

### Claim 10 (depends on 1)

The method of claim 1, wherein the haloperoxidase is administered in a first composition together with at least one further composition comprising one or more of:
a halide,
peroxide or a peroxide-producing oxidase, and
a substrate for the peroxide-producing oxidase.

### Claim 11 (depends on 10)

The method of claim 10, wherein said compositions are:
premixed before administration, or
administered concurrently or sequentially.

### Claim 12 (depends on 1)

The method of claim 1, wherein the solid cancer is a tumor, preferably a primary or metastatic tumor.

### Claim 13 (depends on 12)

The method of claim 12, wherein the haloperoxidase is administered extratumorally or intratumorally.

### Claim 14 (depends on 1)

The method of claim 1, wherein the solid cancer is selected from the group consisting of: breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, kidney and renal pelvis cancer, endometrial cancer, pancreatic cancer, thyroid cancer, liver cancer, brain cancer and spinal cord cancer.

### Claim 15

A method of treating a solid cancer in a patient, said method consisting of administering to said patient an effective amount of:
a haloperoxidase, and optionally one or more of:
a halide,
a peroxide or peroxide producing oxidase,
a substrate for said oxidase, and a
a pharmaceutically acceptable carrier.

### Claim 16

A combination for treating a solid cancer in a patient, said combination comprising:
a haloperoxidase, and at least one of
a halide, and
peroxide or a peroxide producing oxidase.

### Claim 17 (depends on 16)

The combination of claim 16, wherein the haloperoxidase catalyzes halide oxidation and disproportionation of peroxide yielding singlet molecular oxygen resulting in one or more of:
inhibition of cancer cell growth,
inhibition of cancel cell metastases, and/or
cancer cell death.

### Claim 18 (depends on 16)

The combination of claim 16, which is formulated in a composition that is for administration to said patient.

### Claim 19 (depends on 16)

The combination of claim 16, which is formulated in at least two compositions, and wherein said compositions are:
premixed for administration to said human or animal subject, or
for administration concurrently or sequentially to said human or animal subject.

### Claim 20 (depends on 16)

The combination of claim 16, wherein the haloperoxidase is selected from a group consisting of: myeloperoxidase (MPO), eosinophil peroxidase (EPO), lactoperoxidase (LPO), chloroperoxidase (CPO), functional derivatives thereof, and combinations thereof.

### Claim 21 (depends on 16)

The combination of claim 16, wherein the peroxide-producing oxidase is glucose oxidase.

### Claim 22 (depends on 16)

The combination of claim 16, wherein the halide is chloride or bromide.

### Claim 23 (depends on 16)

The combination of claim 16, comprising from about 1 μg/ml to about 50,000 μg/ml of haloperoxidase.

### Claim 24 (depends on 16)

The combination of claim 16, wherein the peroxide-producing oxidase generates from 100 pmol to 50 μmol peroxide per ml per minute when in the presence of a substrate for the oxidase.

### Claim 25 (depends on 16)

The combination of claim 16, wherein the solid cancer is a tumor, and wherein the combination is formulated for administration extratumorally or intratumorally.

### Claim 26 (depends on 16)

The combination of claim 16, wherein the solid cancer is selected from the group consisting of: breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, kidney and renal pelvis cancer, endometrial cancer, pancreatic cancer, thyroid cancer, liver cancer, brain cancer and spinal cord cancer.

### Claim 27

A combination for treating a solid tumor in a patient, said combination consisting of:
a haloperoxidase,
a halide, and
peroxide or a peroxide producing oxidase, and optionally
a substrate for said oxidase, and
a pharmaceutically acceptable carrier.

### Claim 28

A composition for treating a solid cancer in a patient, said composition comprising:
a haloperoxidase, and optionally one or more of:
a halide,
peroxide or a peroxide producing oxidase,
a substrate for said oxidase, and
a pharmaceutically acceptable carrier.

### Claim 29 (depends on 28)

The composition of claim 28, wherein the haloperoxidase is selected from a group consisting of: myeloperoxidase (MPO), eosinophil peroxidase (EPO), lactoperoxidase (LPO), chloroperoxidase (CPO), functional derivatives thereof, and combinations thereof.

### Claim 30 (depends on 28)

The composition of claim 28, wherein the haloperoxidase catalyzes halide oxidation and disproportionation of peroxide yielding singlet molecular oxygen resulting in one or more of:
inhibition of cancer cell growth,
inhibition of cancel cell metastases, and/or
cancer cell death.

### Claim 31 (depends on 28)

The composition of claim 28, in which is the haloperoxidase is formulated together with a peroxide producing oxidase.

### Claim 32 (depends on 28)

The composition of claim 28, wherein the peroxide-producing oxidase is glucose oxidase.

### Claim 33 (depends on 28)

The composition of claim 28, comprising from about 1 to about 50,000 μg/ml of haloperoxidase.

### Claim 34 (depends on 28)

The composition of claim 28, wherein the peroxide-producing oxidase generates from 100 μmol to 50 μmol peroxide per ml per minute when in the presence of a substrate for the oxidase.

### Claim 35 (depends on 28)

The composition of claim 28, wherein said composition comprises about 10 to about 5,000 μg/ml of haloperoxidase, and from about 1 to about 500 U/ml of glucose oxidase.

### Claim 36 (depends on 26)

The composition of claim 26, wherein the solid cancer is a tumor, and wherein the composition is formulated for administration extratumorally or intratumorally.

### Claim 37 (depends on 26)

The composition of claim 26, wherein the solid cancer is selected from the group consisting of: breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, kidney and renal pelvis cancer, endometrial cancer, pancreatic cancer, thyroid cancer, liver cancer, brain cancer and spinal cord cancer.

### Claim 38

A composition for treating a solid cancer in a patient, said composition consisting of:
a haloperoxidase, and optionally one or more of
a halide,
peroxide or a peroxide producing oxidase,
a substrate for said oxidase, and
a pharmaceutically acceptable carrier.
